Understanding the RECORDS 3 Trial and its impact on anticiagulation practice in resource poor countries.
Venous thromboembolism is a significant cause of mortality and morbidity in patients following major orthopaedic surgeries. The RECORDS 3 trial revolutionised anticoagulation practice especially in patients with total knee arthroplasty and challenging the strong hold of warfarin and heparin in anticoagulation practice. With all these novel agents shifting the paradigm in anticoagulation management, Cost, in accessibility and lack of awareness of the availability of the agents amongst clinicians and surgeons alike are some factors militating against the use of these agents in patients in resource poor countries.
Department of Haematology and Immunology, Bleeding and Thrombosis Unit, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria.
T U
TU
Nwagha
Department of Pathology, Hematology Unit, Braithwaite Memorial Specialist Hospital, Port Harcourt, Rivers State, Nigeria.
H E
HE
Omunakwe
D000925:Anticoagulants / Q000008:administration & dosage*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D000069552:Rivaroxaban / Q000008:administration & dosage*; D054556:Venous Thromboembolism / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage*
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014859:Warfarin; D000069552:Rivaroxaban